Stock Events

Stock Events

Tango Therapeutics 

$32.29
25
+$0.13+0.4% Today

Statistics

Day High
34.39
Day Low
31.52
52W High
34.39
52W Low
4.6
Volume
2,803,334
Avg. Volume
3,661,382
Mkt Cap
4.35B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.37
-0.2
-0.03
0.14
Expected EPS
-0.323542
Actual EPS
N/A

Financials

-309.73%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
84.14MRevenue
-260.6MNet Income

Analyst Ratings

39.00Average Price Target
The highest estimate is 69.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
78%
Hold
22%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TNGX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.9B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Tango Therapeutics' approach to targeting cancer.
Intellia Therapeutics
NTLA
Mkt Cap1.69B
Intellia Therapeutics is a leading developer of CRISPR gene editing, directly competing in the genetic medicine space.
Editas Medicine
EDIT
Mkt Cap383.65M
Editas Medicine operates in the CRISPR gene editing sector, offering technologies that could rival Tango's cancer therapies.
Beam Therapeutics
BEAM
Mkt Cap2.99B
Beam Therapeutics focuses on base editing, a form of gene editing that could offer alternative treatments to those developed by Tango.
Sangamo Therapeutics
SGMO
Mkt Cap62.14M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the same therapeutic areas as Tango.
Allogene Therapeutics
ALLO
Mkt Cap655.79M
Allogene Therapeutics is focused on allogeneic CAR T-cell therapies, which could be in direct competition with Tango's cancer treatment approaches.
Fate Therapeutics
FATE
Mkt Cap240.11M
Fate Therapeutics is working on programmed cellular immunotherapies, which could compete with Tango's cancer treatment strategies.
Novartis
NVS
Mkt Cap292.07B
Novartis is a large pharmaceutical company with a broad portfolio, including advanced therapies that could compete with Tango's cancer treatments.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences, with its acquisition of Kite Pharma, has a strong presence in cell therapy for cancer, competing with Tango Therapeutics.

About

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Show more...
CEO
Dr. Barbara L. Weber M.D.
Employees
155
Country
United States
ISIN
US87583X1090

Listings

XNAS
US
TNGX
BOATS
BOATS
TNGX.BOATS

0 Comments

Share your thoughts

FAQ

What is Tango Therapeutics stock price today?▼
The current price of TNGX is $32.29 USD — it has increased by +0.4% in the past 24 hours. Watch Tango Therapeutics stock price performance more closely on the chart.
What is Tango Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tango Therapeutics stocks are traded under the ticker TNGX.
Is Tango Therapeutics stock price growing?▼
TNGX stock has risen by +12.59% compared to the previous week, the month change is a +57.4% rise, over the last year Tango Therapeutics has showed a +572.01% increase.
What is Tango Therapeutics market cap?▼
Today Tango Therapeutics has the market capitalization of 4.35B
When is the next Tango Therapeutics earnings date?▼
Tango Therapeutics is going to release the next earnings report on August 12, 2026.
What were Tango Therapeutics earnings last quarter?▼
TNGX earnings for the last quarter are -0.32 USD per share, whereas the estimation was -0.31 USD resulting in a -2.01% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tango Therapeutics revenue for the last year?▼
Tango Therapeutics revenue for the last year amounts to 84.14M USD.
What is Tango Therapeutics net income for the last year?▼
TNGX net income for the last year is -260.6M USD.
How many employees does Tango Therapeutics have?▼
As of June 17, 2026, the company has 155 employees.
In which sector is Tango Therapeutics located?▼
Tango Therapeutics operates in the Health & Wellness sector.
When did Tango Therapeutics complete a stock split?▼
Tango Therapeutics has not had any recent stock splits.
Where is Tango Therapeutics headquartered?▼
Tango Therapeutics is headquartered in Boston, United States.